Status:

RECRUITING

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

Lead Sponsor:

Jupiter Endovascular

Conditions:

Pulmonary Embolism

Eligibility:

All Genders

18-79 years

Phase:

NA

Brief Summary

This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and sympto...

Detailed Description

The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptom...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age ≥ 18 years \< 80 years
  • Acute onset of symptoms ≤ 14 days consistent with the presence of pulmonary embolism.
  • CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  • RV/LV ratio of \> 0.9 on CTA as assessed by investigator (site determined).
  • Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
  • Subject or subject's legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care Protocol-specific procedures
  • Subject is willing and able to comply with all Protocol-required follow-up visits
  • Exclusion Criteria
  • Thrombolytic use within 30 days of baseline CTA
  • Pulmonary hypertension with peak pulmonary artery pressure \> 70 mmHg by right heart catheterization (site determined)
  • Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
  • Unstable heart rate \> 130 beats per minute prior to procedure
  • FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
  • Hematocrit \< 28%
  • Platelets \< 100,000/μL
  • Serum baseline creatinine \> 1.8 mg/dL
  • International normalized ratio (INR) \> 3
  • Major trauma injury severity score (ISS) \> 15 within the past 14 days
  • Presence of intracardiac lead in the right ventricle or right atrium placed \<180 days prior to the index procedure
  • Cardiovascular or pulmonary surgery within last 30 days
  • Actively progressing cancer requiring chemotherapy
  • Known bleeding diathesis or coagulation disorder
  • Left bundle branch block
  • History of severe or chronic pulmonary arterial hypertension
  • History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  • History of decompensated heart failure
  • Patients on extracorporeal membrane oxygenation (ECMO)
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • History of heparin-induced thrombocytopenia (HIT)
  • Contraindication to systemic or therapeutic doses of heparin or anticoagulants
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention
  • Life expectancy of \< 365 days, as determined by Investigator
  • Female who is pregnant or nursing
  • Current participation in another investigational drug or device treatment study
  • Inability to lay flat for procedure
  • Known presence of right-to-left cardiac shunt
  • History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  • Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

Exclusion

    Key Trial Info

    Start Date :

    October 15 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2026

    Estimated Enrollment :

    145 Patients enrolled

    Trial Details

    Trial ID

    NCT06576427

    Start Date

    October 15 2024

    End Date

    March 1 2026

    Last Update

    November 26 2025

    Active Locations (23)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (23 locations)

    1

    Hartford Hospital

    Hartford, Connecticut, United States, 06102

    2

    Ascension Sacred Heart

    Pensacola, Florida, United States, 32504

    3

    Emory University

    Atlanta, Georgia, United States, 30322

    4

    Henry Ford Hospital

    Detroit, Michigan, United States, 48202